Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of KB707 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies

Clinical Trial Details

This clinical trial is for men and women with locally advanced or metastatic solid tumor malignancies who have progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy.

The purpose of this study is to evaluate the safety and effectiveness of KB707. KB707 is experimental, which means that it is being tested and is not yet approved by the United States Food and Drug Administration (FDA).

In this study, all participants will receive intratumoral injections of KB707 into measurable, injectable lesions. The study team will discuss the injections and doses with each participant. 
Participation is expected to last up to 3 years.

Key Eligibility: 
  1. Open to men and women above the age of 18 who have been diagnosed with locally advanced or metastatic solid tumor and the individual has progressed on standard of care therapy.
  2. Participants must not have received prior oncology therapy (chemotherapy, immunotherapy, biological therapy) or use of an investigational agent or an investigational device within 21 days of first dose of KB707

Detailed eligibility will be reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan


Alexa Charney, NP
646) 962-6444

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:






Open to Enrollment

Age Group